Company / Cash & Equivalents
GE HealthCare Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.5B
FY2025
5-year range
$1.4B / $4.5B
FY2022-FY2025
Trend
+56.3%
vs FY2024
Sector context
#8 of 148
Health Care
What the data says
Among 148 Health Care companies, GE HealthCare is in the top 5% for cash & equivalents. Cash & Equivalents has increased for 3 consecutive years, from $1.4B in FY2022 to $4.5B in FY2025.
Based on SEC 10-K filings.
$4.5B in FY2025 with a 3-year CAGR of +46.1%. Top quartile in the Health Care sector.
Improved from $2.5B to $4.5B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +46.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 148This company $4.5B Sector average $1.2B
▼
+281.7% above sector average
Key checks
Key Insights
- GE HealthCare's cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +46.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 56.3% year-over-year.
- Ranks #8 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.14 (distress zone, below 1.8 threshold)
- Strong return on equity: 22.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.5B | +56.3% |
| FY2024 | $2.9B | +15.2% |
| FY2023 | $2.5B | +73.2% |
| FY2022 | $1.4B | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026